Capadiso, Rhian .
HRN: 28-13-80 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/25/2025
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
11/25/2025
12/02/2025
PO
3mL
2x/day
AGE With Mod DHN
Checking Final Appropriateness
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes